Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 14/2001

01.12.2001 | Adis New Indication Profile

Orlistat

In the Prevention and Treatment of Type 2 Diabetes Mellitus

verfasst von: Gillian M. Keating, Blair Jarvis

Erschienen in: Drugs | Ausgabe 14/2001

Einloggen, um Zugang zu erhalten

Abstract

  • ▴ Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat.
  • ▴ A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience an improvement, and less likely to experience a deterioration, in glucose tolerance status than placebo recipients.
  • ▴ In comparison with placebo, orlistat recipients had significantly greater reductions in glycosylated haemoglobin and fasting plasma glucose levels in large, double-blind, randomised, placebo-controlled studies of 24 to 52 weeks’ duration involving patients with obesity and type 2 diabetes mellitus. In one such study, the dosage of concomitant sulphonylureas was able to be reduced in more orlistat than placebo recipients (43.2 vs 28.9%), with discontinuation of sulphonylurea therapy achieved in 11.7% of orlistat recipients.
  • ▴ The most common adverse effects reported in orlistat recipients with type 2 diabetes mellitus relate to the gastrointestinal system and are similar to those reported in studies involving patients without type 2 diabetes mellitus.
Literatur
1.
Chan JM, Stampfer MJ, Rimm EB, et al. Obesity, fat distibution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994 Sep; 17: 961–9PubMedCrossRef
2.
Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995 Apr 1; 122: 481–6PubMed
3.
Hauner H. The impact of pharmacotherapy on weight management in type 2 diabetes. Int J Obes Relat Metab Disord 1999 Jun; 23 Suppl 7: S12–7PubMedCrossRef
4.
Tremble JM, Donaldson D. Is continued weight gain inevitable in type 2 diabetes mellitus? J R Soc Health 1999 Dec; 119: 235–9CrossRef
5.
Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: Application to type 2 diabetes. Diabetes Care 1997; 20(11): 1744–66PubMed
6.
Gumbiner B. The treatment of obesity in type 2 diabetes mellitus. Primary Care Clinics in Office Practice 1999; 26(4): 869–83PubMedCrossRef
7.
Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 16: 397–415
8.
Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987 Oct; 147: 1749–53PubMedCrossRef
9.
National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Available from URL: http/​Avww.​nhlbi.​nih.​gov [Accessed 2001 Jun 8]
10.
Guerciolini R. Mode of action of orlistat. Int J Obes 1997 Jun; 21 Suppl. 3: 12–23
11.
Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999 Oct; 58: 743–60PubMedCrossRef
12.
Finer N, James WPT, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes 2000; 24: 306–13CrossRef
13.
Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: one 1-y study. Am J Clin Nutr 1999; 69: 1108–16PubMed
14.
Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000 Sep; 248: 245–54PubMedCrossRef
15.
Rössner S, Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. J Obes Res 2000 Jan; 8: 49–61CrossRef
16.
Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000 Feb; 9: 160–7PubMedCrossRef
17.
Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998 Jul 18; 352: 167–72PubMedCrossRef
18.
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999 Jan 20; 281: 235–42PubMedCrossRef
19.
Krempf M, Louvet J-P, Allanic H, et al. Orlistat associated with a hypocaloric diet in obese patients promotes and maintains weight loss during an 18-month period [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 21
20.
Toplak H. Efficacy and safety of orlistat plus a reduced-calorie diet in obese non-diabetic patients: a 1-year Austrian multicentre study [abstract]. Int J Obes 2001 May; 25 Suppl. 2: S112
21.
Drent ML, Larsson I, Williamolsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995 Apr; 19: 221–6
22.
Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 54: 125–32PubMedCrossRef
23.
Borovicka J, Schwizer W, Guttmann G, et al. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut 2000 Jun; 46: 774–81PubMedCrossRef
24.
Hadváry P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988; 256: 357–61PubMed
25.
Lüthi-Peng Q, Winkler FK. Large spectral changes accompany the conformational transition of human pancreatic lipase induced by acylation with the inhibitor tetrahydrolipstatin. Eur J Biochem 1992 Apr 1; 205: 383–90PubMedCrossRef
26.
Shepard TY, Jensen DR, Blotner S, et al. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers. Int J Obes Relat Metab Disord 2000 Feb; 24: 187–94PubMedCrossRef
27.
Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994 Jul; 56: 82–5PubMedCrossRef
28.
Bachmann OP, Dahl DB, Brechtel K, et al. Orlistat (Xenical®) improves insulin sensitivity in obese intentionally weight maintaining subjects [abstract]. Diabetes Res Clin Pract 2000 Sep; 50 Suppl. 1: 70CrossRef
29.
Adnan G, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity [abstract]. Int J Obes 2001 May; 25 Suppl. 2: S111
30.
Chan JCN, Tong PC, Lee ZSK, et al. Effect of orlistat on cardiovascular risk factors and insulin sensitivity in young obese Chinese type 2 diabetic patients [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 108CrossRef
31.
McCann S, McDuffie J, Nicholson J, et al. A pilot study of the efficacy of orlistat in overweight adolescents [abstract]. J Obes Res 2000 Oct; 8 Suppl. 1: 58
32.
Suter PM, Marmier G, Veya-Linder C, et al. Effect of orlistat on postprandial metabolism in healthy subjects [abstract]. J Obes Res 2001; 9 Suppl. 3: 68
33.
Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 Nov; 35: 1103–8PubMed
34.
Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed Orlistat in obese/overweight volunteers. J Clin Pharmacol 1996 Nov; 36: 1006–11PubMedCrossRef
35.
Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999; 39(1): 41–6PubMedCrossRef
36.
37.
Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 647–53PubMed
38.
Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol 1996; 36: 152–9PubMed
39.
Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995; 35: 521–5PubMed
40.
Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady-date in human volunteers. Roche, 2001. (Data on file)
41.
Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 659–66PubMed
42.
Oo CY, Akbari B, Lee S, et al. Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia. Clin Drug Invest 1999 Mar; 17: 217–23CrossRef
43.
Mück W, Adelmann H-G, Ruf T, et al. Lack of pharmacokinetic drug-drug interaction between orlistat and cerivastatin. Clin Drug Invest 2000 Jan; 19: 71–3CrossRef
44.
Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995 Aug; 35: 840–3PubMed
45.
Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 654–8PubMed
46.
Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996 Apr; 36: 352–5PubMed
47.
Weber C, Tam YK, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996 Sep; 51: 87–90PubMedCrossRef
48.
Hartmann D, Güzelhan C, Zuiderwijk PBM. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996; 50: 421–4PubMedCrossRef
49.
Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998; 54: 773–7PubMedCrossRef
50.
Le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient [letter]. Transplantation 2000 Nov 27; 70: 1541–2PubMedCrossRef
51.
Nägele H, Petersen B, Bonacker U, et al. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant recipient. Eur J Clin Pharmacol 1999; 55: 667–9PubMedCrossRef
52.
Schnetzler B, Kondo-Oestreicher M, Vala D, et al. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes [letter]. Transplantation 2000 Nov 27; 70: 1540–1PubMedCrossRef
53.
Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000 May 8; 160: 1321–6PubMedCrossRef
54.
Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16: 2013–7PubMedCrossRef
55.
Lee KK, You JH, Ho SS, et al. A pharmacoeconoic analysis of weight-reduction therapy in a hypothetical cohort of obese Chinese patients with impaired glucose tolerance [abstract]. Value in Health 2001 Mar–Apr; 4(2): 116CrossRef
56.
Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21: 1288–94
57.
Hawkins F, Duran S, Vilardell E, et al. Orlistat promotes glucemia control and other cardiovascular risk factors lowering in obese patients with type 2 diabetes: randomised clinical trial [abstract]. Diabetologia 2000 Aug; 43 Suppl. 1: 171
58.
Miles JM, Aronne LJ, Hollander P, et al. Effect of orlistat in overweight and obese type 2 diabetes patients treated with metformin [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 442–3CrossRef
59.
Bray GA, Pi-Sunyer FX, Hollander P, et al. Effect of orlistat in overweight patients with type 2 diabetes receiving insulin therapy [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 107
60.
Deerochanawong C. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 433
61.
Halpern A. Latin-American multicentric study with orlistat in overweight or obese patients with type diabetes [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 437
62.
Guy-Grand B, Valensi P, Droun P, et al. Improvement of metabolic control in obese type 2 diabetic patients treated with orlistat for 6 months [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 436CrossRef
63.
Hanefeld M, Platon J, Sachse G. Orlistat promotes weight loss and improves glycaemic control in overweight patients with type 2 diabetes [abstract]. Diabetologia 2001; 44 Suppl. 1: 231
64.
Hollander P, Lucas C, Hauptman J, et al. Orlistat reduces body weight and cardiovascular disease risk factors in obese men and women with type 2 diabetes [abstract]. Diabetes 1999 May; 48 Suppl. 1: 310
65.
Segal KR, Lucas C, Hauptman J, et al. Effect of weight loss with orlistat on cardiovascular disease risk prediction in type 2 diabetes [abstract]. Diabetes Res Clin Pract. 2000; 50 Suppl. 1: 292CrossRef
66.
Segal KR, Hollander P, Lucas C, et al. Early weight loss response to diet + orlistat predicts long-term improvement in glycemic control in type 2 diabetes [abstract]. Diabetologia 2000 Aug; 43 Suppl. 1: 43
67.
Kelley DE. Impact of orlistat on fasting hyperglycemia in obese patients with type 2 diabetes mellitus [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 439
68.
Hollander P, Miles JM. Effects of orlistat in obese metformin-treated patients with type 2 diabetes: attainment of treatment goals [abstract]. Int J Obes 2001; 25 Suppl. 2: 92
69.
Shi YF, Zhu JR. Effect of orlistat on weight loss and glycemic control in overweight Chinese patients with type 2 diabetes [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 101–2CrossRef
70.
Sea MM, Chong A, Tong PC, et al. The effects of orlistat on body composition in obese diabetic and non-diabetic Chinese adults [abstract]. Diabetes 2001 Jun; 50 Suppl. 2: 108CrossRef
71.
Mendoza-Guadarrama LG, Lopez-Alvarenga JC, Castillo-Martinez L, et al. Orlistat reduces visceral fat independent of weight changes in obese diabetics type 2. Int J Obes Relat Metab Disord 2000 May; 24 Suppl. 1: 167
72.
Klein S, Miles JM. Gastrointestinal effects of orlistat plus metformin in obese patients with type 2 diabetes mellitus [abstract]. Int J Obes 2001; 25 Suppl. 2: 92
Metadaten
Titel
Orlistat
In the Prevention and Treatment of Type 2 Diabetes Mellitus
verfasst von
Gillian M. Keating
Blair Jarvis
Publikationsdatum
01.12.2001
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 14/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161140-00011

Weitere Artikel der Ausgabe 14/2001

Drugs 14/2001 Zur Ausgabe

Adis Drug Profile

Darbepoetin Alfa

Adis Drug Profile

Orlistat

Therapy in Practice

Premenstrual Asthma

Current Opinion

Pancreatic Islet Cell Transplantation

Adis Drug Evaluation

Amisulpride

Review Article

The Use of Silymarin in the Treatment of Liver Diseases